Table 2. Repeated Biopsy Results at the 6-Month Follow-up.
| Ablation group, No. (%) | P value | ||
|---|---|---|---|
| Focal (n = 48) | Extended (n = 53) | ||
| Clinically significant prostate cancer | 9 (18.8) | 7 (13.2) | .29 |
| Any-grade prostate cancer | 27 (56.3) | 23 (43.4) | .20 |
| ISUP grade | |||
| 1 | 18 (37.5) | 16 (30.2) | |
| 2 | 7 (14.6) | 3 (5.7) | |
| 3 | 1 (2.1) | 4 (7.5) | |
| ≥4 | 1 (2.1) | 0 | |
| No. of positive cores | .11 | ||
| 1 | 15 (31.3) | 14 (26.4) | |
| 2 | 6 (12.5) | 8 (15.1) | |
| ≥3 | 6 (12.5) | 1 (1.9) | |
| Location of positive cores | .09 | ||
| In the treated area | 3 (6.3) | 9 (17.0) | |
| Out of the treated area | 17 (35.4) | 10 (18.9) | |
| In and out of the treated area | 5 (10.4) | 2 (3.8) | |
| Treatment failurea | 12 (25.0) | 12 (22.6) | .82 |
Abbreviation: ISUP, International Society of Urological Pathology.
a
Treatment failure was defined as persistent cancer of similar or different grade in the treated area or high volume (≥3 mm) ISUP grade 1 tumor foci or ISUP grade 2 tumor foci found in the untreated area.